This research combines focused ultrasound and engineered genetic circuits to activate cancer immunotherapy directly within solid tumors. By locally triggering immune-stimulating cytokines such as IL-12, the approach aims to convert “cold” tumors into “hot” tumors while minimizing systemic toxicity, potentially expanding curative immunotherapy treatments to more cancer patients.

This research develops synthetic genetic circuits that automatically alternate CAR T-cell activity between active cancer killing and recovery states. By preventing immune-cell exhaustion, these circuits could improve cancer immunotherapy effectiveness. The work also suggests broader biomedical applications where controlled cycling of gene activity may enhance treatment safety, longevity, and therapeutic performance.